TP-05: An investigational therapeutic for the prevention of Lyme disease2
What is TP-05?
TP-05 is an oral, systemic formulation of lotilaner in development for the prevention of Lyme disease.2
Currently, there is no FDA-approved pharmacologic option for the prevention of Lyme disease.2
TP-05 is1,2:
-
Believed to be the only non-vaccine, drug-based, preventive therapeutic in development that targets and kills infected tick vectors before they can transmit the Borrelia bacteria that causes Lyme disease
-
An oral formulation intended to rapidly provide systemic blood levels of lotilaner, a well-characterized anti-parasitic agent, for on-demand protection
-
Currently being evaluated in a Phase 2a trial
Learn more about our efforts to prevent Lyme disease.
References
1. Tarsus reports full-year 2022 financial results and recent business achievements. News release. Tarsus Pharmaceuticals, Inc. March 13, 2023. Accessed August 11, 2023. https://ir.tarsusrx.com/news-releases/news-release-details/tarsus-reports-full-year-2022-financial-results-and-recent 2. Tarsus Pharmaceuticals, Inc. initiates phase 1 Callisto trial of TP-05, a novel, oral, non-vaccine therapeutic for the prevention of Lyme disease. News release. Tarsus Pharmaceuticals, Inc. June 16, 2021. Accessed August 11, 2023. https://ir.tarsusrx.com/news-releases/news-release-details/tarsus-pharmaceuticals-inc-initiates-phase-1-callisto-trial-tp
15440 Laguna Canyon Road, Ste 160
Irvine, CA 92618
2024 Tarsus Pharmaceuticals, Inc. All rights reserved. TARSUS, XDEMVY, and the associated logo are trademarks of Tarsus Pharmaceuticals, Inc.
From Fortune. ©2023 Fortune Media IP Limited. All rights reserved. Used under license. Fortune and Fortune Media IP Limited are not affiliated with, and do not endorse the products or services of, Tarsus.
Contact Tarsus
Please reach out to us using the form below.
"*" indicates required fields